Ahmed AlBadri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ahmed AlBadri has a total of 88 co-authors. Here are the top co-authors by number of shared publications:
Janet Wei
Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA
3 shared publicationsAilin Barseghian El-Farra
Department of Medicine, Division of Cardiology, University of California, Irvine, California, USA
2 shared publicationsAllen Jeremias
St Francis Hospital & Heart Center, Roslyn, New York, USA
2 shared publicationsAmir Lerman
Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA
2 shared publications- Arshed A. Quyyumi
Emory University School of Medicine
2 shared publications Bruce A. Samuels
Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA
2 shared publications
Latest Publications
- Top Cited Papers
Comprehensive Management of ANOCA, Part 1—Definition, Patient Population, and Diagnosis
- Top Cited Papers
Comprehensive Management of ANOCA, Part 2—Program Development, Treatment, and Research Initiatives
- Open Access
- 1 September 2023
- Published by PCR Digital & Publishing in EuroIntervention
- Vol. 19 (7) , 600-601
Transcatheter edge-to-edge repair with the PASCAL device for failed MitraClip procedure
Case report of unsuccessful MitraClip TEER for severe mitral regurgitation due to inability to correct trajectory, but successful PASCAL TEER two months later through same access site in the same patient.
- 1 September 2023
- Published by PCR Digital & Publishing in EuroIntervention
- Vol. 19 (7) , 600-601
Open AccessTranscatheter edge-to-edge repair with the PASCAL device for failed MitraClip procedure
Case report of unsuccessful MitraClip TEER for severe mitral regurgitation due to inability to correct trajectory, but successful PASCAL TEER two months later through same access site in the same patient.
- 13 March 2023
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 16 (5) , 542-554
Hemodynamic and Mid-Term Outcomes for Transcatheter Aortic Valve Replacement in Degenerated Internally Stented Valves
- 13 March 2023
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 16 (5) , 542-554
Hemodynamic and Mid-Term Outcomes for Transcatheter Aortic Valve Replacement in Degenerated Internally Stented Valves
- Open Access
- 21 April 2020
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 9 (8) , e015515
Soluble Urokinase‐Type Plasminogen Activator Receptor and High‐Sensitivity Troponin Levels Predict Outcomes in Nonobstructive Coronary Artery Disease
Background: Multiple biomarkers have been independently and additively associated with major adverse cardiovascular events in patients with coronary artery disease. We investigated the prognostic value of suPAR (soluble urokinase‐type plasminogen activator receptor) and hsTnI (high‐sensitivity troponin I) levels in symptomatic patients with no obstructive coronary artery disease. We hypothesized that high levels of these biomarkers will be associated with the risk of future adverse outcomes. Methods and Results: Plasma levels of suPAR and hsTnI were measured in 556 symptomatic patients with no obstructive coronary artery disease. A biomarker risk score was calculated by counting the number of biomarkers above the median in this cohort (suPAR>2523 pg/mL and hsTnI>2.7 pg/mL). Survival analyses were performed with models adjusted for traditional risk factors. All‐cause death and major adverse cardiovascular events (cardiovascular death, myocardial infarction, stroke, and heart failure) served as clinical outcomes over a median follow‐up of 6.2 years. Mean age was 57±10 years, 49% of the cohort patients were female, and 68% had a positive stress test. High suPAR and hsTnI levels were independent predictors of all‐cause death (hazard ratio=3.2 [95% CI, 1.8–5.7] and 1.3 [95% CI, 1.0–1.7], respectively; both P P <0.002). Compared with a biomarker risk score of 0, biomarker risk scores of 1 and 2 were associated with 19‐ and 14‐fold increased risk of death and development of major adverse cardiovascular events, respectively. Conclusions: Among symptomatic patients with no obstructive coronary artery disease, higher levels of suPAR and hsTnI were independently and additively associated with an increased risk of adverse events. Whether modification of these biomarkers will improve risk in these patients needs further investigation.
- 21 April 2020
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 9 (8) , e015515
Open AccessSoluble Urokinase‐Type Plasminogen Activator Receptor and High‐Sensitivity Troponin Levels Predict Outcomes in Nonobstructive Coronary Artery Disease
Background: Multiple biomarkers have been independently and additively associated with major adverse cardiovascular events in patients with coronary artery disease. We investigated the prognostic value of suPAR (soluble urokinase‐type plasminogen activator receptor) and hsTnI (high‐sensitivity troponin I) levels in symptomatic patients with no obstructive coronary artery disease. We hypothesized that high levels of these biomarkers will be associated with the risk of future adverse outcomes. Methods and Results: Plasma levels of suPAR and hsTnI were measured in 556 symptomatic patients with no obstructive coronary artery disease. A biomarker risk score was calculated by counting the number of biomarkers above the median in this cohort (suPAR>2523 pg/mL and hsTnI>2.7 pg/mL). Survival analyses were performed with models adjusted for traditional risk factors. All‐cause death and major adverse cardiovascular events (cardiovascular death, myocardial infarction, stroke, and heart failure) served as clinical outcomes over a median follow‐up of 6.2 years. Mean age was 57±10 years, 49% of the cohort patients were female, and 68% had a positive stress test. High suPAR and hsTnI levels were independent predictors of all‐cause death (hazard ratio=3.2 [95% CI, 1.8–5.7] and 1.3 [95% CI, 1.0–1.7], respectively; both P P <0.002). Compared with a biomarker risk score of 0, biomarker risk scores of 1 and 2 were associated with 19‐ and 14‐fold increased risk of death and development of major adverse cardiovascular events, respectively. Conclusions: Among symptomatic patients with no obstructive coronary artery disease, higher levels of suPAR and hsTnI were independently and additively associated with an increased risk of adverse events. Whether modification of these biomarkers will improve risk in these patients needs further investigation.
- Open Access
- 12 June 2017
- Published by Wiley in Clinical Cardiology
- Vol. 40 (10) , 886-891
Typical angina is associated with greater coronary endothelial dysfunction but not abnormal vasodilatory reserve
Background: Typical angina (TA) is defined as substernal chest pain precipitated by physical exertion or emotional stress and relieved with rest or nitroglycerin. Women and elderly patients are usually have atypical symptoms both at rest and during stress, often in the setting of nonobstructive coronary artery disease (CAD).Hypothesis: To further understand this, we performed subgroup analysis comparing subjects who presented with TA vs nontypical angina (NTA) using baseline data of patients with nonobstructive CAD and coronary microvascular dysfunction (CMD) enrolled in a clinical trial.Methods: 155 subjects from the RWISE study were divided into 2 groups based on angina characteristics: TA (defined as above) and NTA (angina that does not meet criteria for TA). Coronary reactivity testing (responses to adenosine, acetylcholine, and nitroglycerin), cardiac magnetic resonance–determined myocardial perfusion reserve index (MPRI), baseline Seattle Angina Questionnaire (SAQ), and Duke Activity Status Index (DASI) scores were evaluated.Results: The mean age was 55 ± 10 years; Overall, 30% of subjects had TA. Baseline shortness of breath, invasively assessed acetylcholine‐mediated coronary endothelial function, and SAQ score were worse in the TA group (all P < 0.05), whereas adenosine‐mediated coronary flow reserve, MPRI, and DASI score were similar to the NTA group.Conclusions: Among subjects with CMD and no obstructive CAD, those with TA had more angina pectoris, shortness of breath, and worse quality of life, as well as more severe coronary endothelial dysfunction. Typical angina in the setting of CMD is associated with worse symptom burden and coronary endothelial dysfunction. These results indicate that TA CMD subjects represent a relatively new CAD phenotype for future study and treatment trials.
- 12 June 2017
- Published by Wiley in Clinical Cardiology
- Vol. 40 (10) , 886-891
Open AccessTypical angina is associated with greater coronary endothelial dysfunction but not abnormal vasodilatory reserve
Background: Typical angina (TA) is defined as substernal chest pain precipitated by physical exertion or emotional stress and relieved with rest or nitroglycerin. Women and elderly patients are usually have atypical symptoms both at rest and during stress, often in the setting of nonobstructive coronary artery disease (CAD).Hypothesis: To further understand this, we performed subgroup analysis comparing subjects who presented with TA vs nontypical angina (NTA) using baseline data of patients with nonobstructive CAD and coronary microvascular dysfunction (CMD) enrolled in a clinical trial.Methods: 155 subjects from the RWISE study were divided into 2 groups based on angina characteristics: TA (defined as above) and NTA (angina that does not meet criteria for TA). Coronary reactivity testing (responses to adenosine, acetylcholine, and nitroglycerin), cardiac magnetic resonance–determined myocardial perfusion reserve index (MPRI), baseline Seattle Angina Questionnaire (SAQ), and Duke Activity Status Index (DASI) scores were evaluated.Results: The mean age was 55 ± 10 years; Overall, 30% of subjects had TA. Baseline shortness of breath, invasively assessed acetylcholine‐mediated coronary endothelial function, and SAQ score were worse in the TA group (all P < 0.05), whereas adenosine‐mediated coronary flow reserve, MPRI, and DASI score were similar to the NTA group.Conclusions: Among subjects with CMD and no obstructive CAD, those with TA had more angina pectoris, shortness of breath, and worse quality of life, as well as more severe coronary endothelial dysfunction. Typical angina in the setting of CMD is associated with worse symptom burden and coronary endothelial dysfunction. These results indicate that TA CMD subjects represent a relatively new CAD phenotype for future study and treatment trials.